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CASE REPORT
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Laser and Nd:YAG Low Level Laser Therapy for Medication-related
Osteonecrosis of the Jaw
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ABSTRACT
Medication-Related Osteonecrosis of the Jaw (MRONJ) therapy remains an unresolved problem. The proposed
conservative and surgical treatment regimens are associated to contradictory success rates. Surgical approach
with Er:YAG laser is associated to significant better results compared to medical treatment and traditional surgical
approaches. Objective: To describe a new surgical approach that couples the advantages of the Er:YAG laser and the
usefulness of the AF in highlighting surgical margins. One of the difficulties encountered during surgical removal
of a MRONJ is the precise individuation of necrotic bone margins. Case Report: A case of Stage III mandibular
osteonecrosis treated with a new surgical approach is presented. The aim is to describe an auto-fluorescence (AF)
guided surgical approach performed with Er:YAG laser and Nd:YAG Low Level Laser Therapy (LLLT). After one
month of follow-up, the complete mucosal healing was evident and symptoms was unobserved. Such a technique
allowed a highly accurate and minimally invasive approach through the selective ablation of the non-/hypofluorescent areas. Conclusion: Taking into account the advantages of laser therapy and the possible effectiveness
of the AF in highlighting surgical margins, this approach would probably achieve excellent outcomes.

INTRODUCTION
Bisphosphonates-related osteonecrosis of the jaws
(BRONJ) was defined in 2007 as an area of exposed
bone in the maxillofacial region that does not heal
within eight weeks after identification by a health care
provider in a patient who received bisphosphonates
therapy (BPT) and had not received radiation therapy
to the craniofacial region.1,2

features are present: (1) current or previous treatment
with anti-resorptive or anti-angiogenic agents; (2)
exposed bone or bone that can be probed through an
intraoral or extraoral fistula(e) in the maxillofacial
region that has persisted for more than eight weeks;
and (3) no history of radiation therapy to the jaws or
obvious metastatic disease to the jaws.

In order to accommodate the growing number of
osteonecrosis cases associated with other antiresorptive and anti-angiogenic therapies, the American
Association of Oral and Maxillofacial Surgeons
(AAOMS) with a Position Paper in May 2014, changed
the term in “Medication-Related Osteonecrosis of the
Jaws” (MRONJ).3

To the best of our knowledge, there is no agreement on
the management of such disorder and the success rates
related to the different proposed protocols are very
different and sometimes controversial.4,5

According to the new definition, a patient may be
considered affected with MRONJ if all the following

Many different therapeutic approaches have been
reported such as anti-microbial rinses, antibiotics,
Low Level Laser Therapy (LLLT), local debridement
and surgical resection performed through different
devices, or a combination of these two treatments. As

....
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rates (HR) for nonsurgical approaches were 33% in
Stage 1,24% in Stage 2 and 0% in Stage 3; HR for
conservative surgical approaches were 72% in Stage 1,
79% in Stage 2, and 27% in Stage 3; HR for extensive
surgical approaches were 89% in Stage 0, 87% in
Stage 1, 96% in Stage 2, and 81% in Stage 3 and 100%
in Stage 1, 83% in Stage 2, 100% in Stage 3 for laser
surgical approaches performed through Er:YAG and
Er, Cr: YSGG lasers.6
One of the most frequent difficulty encountered
during the surgical removal of MRONJ is the precise
individuation of necrotic bone margins, usually based
on vascularization, colour and texture of the bone.10,11
Some authors proposed the use of f luorescence
tetracycline-induced in order to discriminate necrotic
from viable bone. Due to its affinity to calcium,
tetracycline is incorporated into the remodelling and
apposition areas of the bone.12,13 It is then incorporated
into viable but not into necrotic bone and can be
visualized by an excitation light of 390 to 430 nm.14,15

Figure 1. Intra-operative view showing a non-exposed stage
II osteonecrosis

Ristow and Pautke in a recent technical note suggested
that even in the absence of tetracycline labelling, the
vital bone could be highlighted on the basis of its AutoFluorescence (AF). Necrotic bone which is lost AF,
appears very dark.16 This condition is possibly caused
by alterations in the extracellular calcified osteoid
matrix or in the bone cells of the necrotic tissue, but
the specific mechanism has not yet been investigated.16
The aim of this paper is to describe a new surgical
approach that couples the advantages of the Er:YAG
laser and the usefulness of the AF in highlighting
surgical margins.

CASE REPORT
A 65-year old female patient was affected by
osteoporosis for which she received 84 doses im of
Alendronic acid. The patient was diagnosed with a
Stage 2 non-exposed osteonecrosis (according to the
AAOMS 2014 staging system) on the right mandible
(Figure 1). Dental anamnesis revealed the extraction of
the premolars and the first molar in the same area four
months before. Computed tomography (CT) scans and
the 3D reconstruction showed a necrosis involving the
vestibular and lingual plates (Figure 2A and B).

Figure 2. Computed Tomography (CT) scan (A) and 3D
reconstruction (B) showing an osteonecrosis that involve
vestibular and lingual plates

Surgical technique
The surgical treatment was performed under local
anaesthesia. Antibiotic therapy with amoxicillin
(2 gram/day) and metronidazole (1 gram/day) was
administered from three days before to three weeks
after intervention. No preoperative tetracycline
labelling was performed.

reported in recent reviews, the success rate for surgical
approaches are approximately 80%.6,7 Particularly,
results obtained with Er:YAG laser-assisted surgical
approaches are significantly better than those obtained
through traditional surgery.8,9
It is worthy to mention here that Rupel et al. in a
systematic review had reported complete healing

After mucoperiosteal flap was performed for affected
bone exposure, the VELscopeTM (LED Medical
...
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Figure 3. A. Clinical photograph of the mucoperiosteal flap of the necrotic area; B. Visualization of the mandibular bone
using VELscopeTM (LED Medical Diagnostics Inc., Barnaby, Canada) showed no or only pale AF

Figure 4. Surgical field after mucoperiosteal flap elevation: A) necrotic bone B) Auto-fluorescence (AF) image showing
hypo-fluorescent (dark) area

Figure 5. 5A,B. Clinical photograph and its AF visualization of the vestibular surface of the removed bone; 5B,C. Clinical
photograph and its AF visualization of the lingual surface of the removed bone showed hyper fluorescent borders

...
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Figure 6. Er:YAG laser evaporation generates bone microperforations in order to stimulate vascularization and
promote healing and attachment of the soft tissue

Figure 7. Clinical photograph at one month after surgery
showed complete mucosal healing

Diagnostics Inc., Barnaby, Canada) system was used
to induce and visualize AF of the mandibular bone. It
was evident that necrotic bone areas showed no or only
pale AF (Figure 3A and B). Osteotomy was performed
through Lindeman bur (Figure 4A and B).

DISCUSSION
The identification of necrotic bone margins during
osteonecrosis removal is a major difficulty for surgeons.
Until now detection of necrosis has been solely based on
radiological diagnostic images (e.g. CT scans, nuclear
magnetic resonance), and on subjective parameters
including the colour, texture and bleeding of the
affected bone.19,20 Some studies reported that bone
bleeding is not always correlated with histological
findings of vital bone.5

After the removal of the necrotic bone block, AF
visualization was used to guide the marginal bone
osteoplasty (Figure 5). A traditional ball-shaped bur
was used to remove sharp angles of the bone due to its
minimum effect on the soft tissues.
According to the AF image obtained after osteoplasy,
Er:YAG laser (Fidelis Plus®, Fotona - Slovenia)
(Parameters: 300 mJ , 30 Hz, fluence of 60 J/cm2)
was used for the vaporization of necrotic bone and for
the detection of healthy bone (Figure 6). This laser is
useful in the removal of additional minimal bone after
osteoplasty. Its action produces micro-spots on the bone
surface for vascularization and promoting healing and
attachment of the soft tissue.25,26

The VELscopeTM device is a non-invasive tool designed
as a first level diagnostic aid for increasing the
diagnostic accuracy (DA) and enhance the specificity
(SP) and sensitivity (SE) of the conventional oral
examination in detecting early mucosal changes.
VELscopeTM emits light in the blue spectrum (400-460
nm) that excites natural fluochromes located within
the epithelium and the submucosa. Fluochromes of the
normal tissues show an AF in the range of the green
colour; while displastic tissues associated with a loss
of autofluorescence (LAF), appear dark in contrast to
the surrounding area.21,22

Moreover, through the minimally invasive action
typical of this device, it is possible to act in the areas
where non-fluorescence or hypo-fluorescence has been
displayed.

A similar effect of LAF has been recently shown in
necrotic bone.13,16 Ristow and Pautke speculated that
such a fluorescence could be caused by alterations in
the extracellular calcified osteoid matrix or in the bone
cells.16 In the present observation, viable bone seems
to emit a very bright AF, in contrast, a LAF seems
to be present in areas of necrotic bone in patients
affected with MRONJ. Consequently, Direct Visual
Intra-operative Fluorescence Examination (DVIFE)
seems to be a suitable guide to visualize necrotic
bone during surgical debridement/resection. DVIFE
as a guide to detect surgical margins of MRONJ is
not invasive, easy to apply and independent from the
subjective impression of the surgeon differently from
the analysis of the clinical appearance of bone and
radiological features.

The patient received an intra-operative irrigations
with povidone iodine solution 10% and application of
low level laser therapy (LLLT) (Nd:YAG laser, 1064
nm, Fidelis Plus, Fotona®, Slovenia – power: 1.25 W;
frequency: 15 Hz; diameter of the fibre: 320 μm) which
was administered in non-focused mode, at 2 mm of
distance from the tissues for 1 minute (power density:
1562.5 W/cm2, fluence 7 J/cm2), five times. A tensionfree wound closure was achieved using continuous
locked suture. The patient received weekly applications
of LLLT for three weeks after intervention.
After one month, the complete mucosal healing was
evident and there was no symptom observed (Figure 7).

...
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CONCLUSION

The VELscopeTM DVIFE uses the AF principles and
therefore pre-operative administration of tetracyclines,
as proposed by some researcher, is not necessary. Due
to its affinity to calcium, tetracycline is incorporated
into the remodelling and apposition areas of bone.
Therefore, it is incorporated into viable but not into
necrotic bone and can be visualized using an excitation
light of 390 to 430nm. 23 Such f luorescence is not
the AF from the bone but apparently it comes from
tetracycline.

This case report shows that Er:YAG laser therapy has
more biological advantages compared to conventional
surgery that would allow the operator to achieve
excellent outcomes for the patient healing process.
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